The FDA has accepted for review the resubmitted BLA for prademagene zamikeracel for recessive dystrophic epidermolysis bullosa.

Bluebird has just two quarters until it’s out of cash. Executives are looking for financing to extend that runway to a ...

Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...

Friday Headlines: 38 y/o Brent Maloy is the first person in SC to undergo gene therapy treatment after living with Hemophilia ...

(BLUE) stock downgraded by Bank of America and J.P. Morgan after the company's Q3 2024 results. Read more here.

Understanding what to patent versus what to keep as a trade secret is an increasingly important and challenging decision ...

The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...

Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...

The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus ...

Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...

A biohacker who is 'reverse aging' has revealed the horrifying side-effect of a procedure to make him look younger.

High cost is a major challenge. The global cell and gene therapy market is projected to expand by $6.56b, reflecting an ...